India's Drug Regulator Clears Phase-1 Human Clinical Trial Of Antisera With Potential To Treat Covid-19
India's Drug Regulator Clears Phase-1 Human Clinical Trial Of Antisera With Potential To Treat Covid-19ICMR Logo

In a major development in the fight against COVID-19, India's drug regulator has approved the human clinical trials of the highly purified antisera for treatment of Covid-19 which has been developed by Indian Council of Medical Research (ICMR) in collaboration with Hyderabad-based Biological E, reports Economic Times.

Developed by injecting an inactivated SARS-CoV-2 in horses, the potential Covid-19 treatment has received the permission of Drug Controller General of India (DCGI) to conduct Phase-1 human clinical trial.

The development was announced on Tuesday (6 October) by ICMR’s Director-General Dr Balram Bhargava.

Antisera are blood serum high in antibodies against specific antigens and are injected in humans to help kickstart the immune system to fight specific infections.

During the study phase, a total of ten healthy horses were immunised with inactivated SARS-CoV-2 and after 21 days of immunisation, plasma samples were tested.

The results indicated the presence of SARS-CoV-2 targeting IgG antibodies. The pre-print version of the study has been posted on the Research Square platform.

An Appeal...

Dear Reader,

As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.

Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.

We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.

Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.

Become A Patron
Become A Subscriber